glp-1 種類 風靡全球「瘦瘦針」Q & A 不只降血糖、減重， 還可治療脂肪肝？！ 索马鲁肽和其他GLP-1 激动剂的严重麻醉风险是否被低估？麻醉患者胃固体内容物残留的病例报告- Anesthesia Patient Safety

Key Findings From 2025 Clinical Trials The year 2025 has already delivered several groundbreaking trials that provide new evidence for cardiovascular outcomes in diabetes: 1

Clinical eligibility for GLP-1 drugs was determined using BMI and the following comorbidities as specified in NHIS: coronary heart disease, prior stroke, prior heart attack, angina, high blood pressure, and high cholesterol

The very short plasmatic half-life represents a major limitation for the possible use of GLP-1 in the clinical setting

It is clear that the CNS is necessary for GLP-1R mediated induction of visceral illness as mice with a CNS deletion of the GLP-1R develop conditioned taste aversion (CTA) to lithium chloride but not to liraglutide (Sisley et al., 2014)

That tends to get the money, so to speak